What is Osteosarcoma?
Osteosarcoma is a rare type of bone cancer that develops when cells that form bone grow uncontrollably, creating malignant tumors. This aggressive cancer most commonly affects children, teenagers, and young adults, typically arising in the long bones near the knee, shoulder, or hip where bone growth is most active. With an incidence of approximately 3.4 cases per million people annually, osteosarcoma represents the most common primary bone tumor in pediatric and adolescent populations. While rare, osteosarcoma requires immediate medical attention and specialized treatment to achieve the best possible outcomes.
Key statistics
| Statistic | Value |
|---|---|
| Annual incidence | 3.4 per million people |
| Peak age of onset | 10-20 years (during periods of rapid bone growth) |
| 5-year survival rate | 60-70% with localized disease, 20-30% with metastatic disease |
| Gender distribution | Slightly more common in males (1.3:1 ratio) |
Symptoms
Primary symptoms: Bone pain, swelling near affected joints, pathologic fractures, limited range of motion, tenderness at tumor site.
The most common early symptom of osteosarcoma is persistent bone pain that worsens over time, particularly at night or during physical activity. Unlike growing pains, this discomfort doesn’t improve with rest and may initially be mistaken for sports injuries or muscle strains. Swelling typically develops around the affected area, most commonly near the knee or shoulder, and may be accompanied by warmth and tenderness. As the tumor grows, it weakens the bone structure, potentially leading to pathologic fractures that occur with minimal trauma or during normal activities. Patients may also experience reduced range of motion in nearby joints, muscle weakness, and in advanced cases, systemic symptoms such as fatigue, weight loss, or fever. A noticeable mass or lump may become visible as the tumor progresses, and some patients report a sensation of the affected limb feeling different or “not right.”
Causes and risk factors
Most cases of osteosarcoma occur sporadically without a clear inherited cause, though both genetic and environmental factors contribute to its development. The cancer typically arises during periods of rapid bone growth, suggesting that the proliferative activity during adolescent growth spurts creates vulnerability to malignant transformation. Genetic risk factors include inherited conditions such as Li-Fraumeni syndrome (involving TP53 gene mutations), hereditary retinoblastoma (RB1 gene), Rothmund-Thomson syndrome, and Paget’s disease of bone. Previous radiation therapy significantly increases osteosarcoma risk, with tumors potentially developing 10-20 years after radiation exposure. Other risk factors include certain chemotherapy agents (particularly alkylating agents), previous benign bone conditions, and genetic syndromes affecting DNA repair mechanisms. Height and rapid growth during adolescence also correlate with increased risk, as taller individuals show higher incidence rates. While most cases appear random, approximately 5-10% occur in the context of cancer predisposition syndromes.
Prevention
No proven methods exist to prevent sporadic osteosarcoma, as most cases arise randomly during normal bone development. However, genetic counseling and testing should be considered for families with cancer predisposition syndromes such as Li-Fraumeni syndrome or hereditary retinoblastoma, where osteosarcoma risk is elevated. Individuals with these genetic conditions may benefit from enhanced surveillance protocols, though specific screening guidelines for osteosarcoma remain limited. For patients who have received radiation therapy, long-term follow-up care should include monitoring for secondary cancers, including osteosarcoma. While lifestyle factors don’t directly prevent osteosarcoma, maintaining overall bone health through adequate nutrition, calcium, and vitamin D intake supports general skeletal wellness. Early recognition of persistent bone pain in children and adolescents remains the most important factor in prompt diagnosis and treatment.
Complications
Without treatment, osteosarcoma rapidly progresses and becomes fatal, with the primary cause of death being pulmonary metastases. The cancer has a strong tendency to spread to the lungs, where secondary tumors interfere with breathing and oxygen exchange. Local tumor growth can cause severe bone destruction, leading to pathologic fractures, nerve compression, and loss of limb function. Advanced cases may develop metastases to other bones, lymph nodes, or organs. Even with treatment, patients face potential long-term complications including limb dysfunction from surgery, growth abnormalities in children, infertility from chemotherapy, cardiac toxicity from certain chemotherapy drugs, hearing loss, kidney damage, and secondary cancers from treatment. Phantom limb pain may occur following amputation, while limb-salvage procedures can lead to infection, implant failure, or functional limitations. Psychological impacts include anxiety, depression, and post-traumatic stress, particularly given the young age of most patients and the intensity of treatment required.
Diagnosis
Osteosarcoma diagnosis requires a systematic approach combining clinical evaluation, imaging studies, and tissue confirmation. Initial assessment includes detailed history focusing on bone pain patterns and physical examination for swelling, tenderness, or masses. Plain radiographs (X-rays) typically show the characteristic “sunburst” pattern, Codman’s triangle, or mixed lytic and blastic bone lesions. Magnetic resonance imaging (MRI) provides detailed information about local tumor extent, soft tissue involvement, and relationship to nearby structures. Computed tomography (CT) of the chest is essential to detect pulmonary metastases, while bone scintigraphy or positron emission tomography (PET) scans identify skeletal metastases. Laboratory tests include complete blood count, comprehensive metabolic panel, lactate dehydrogenase (LDH), and alkaline phosphatase levels, which may be elevated and serve as prognostic markers. Definitive diagnosis requires tissue biopsy, preferably performed by orthopedic oncologists experienced in bone tumor management, as improper biopsy technique can compromise subsequent treatment. Genetic testing of tumor tissue identifies specific mutations that may guide targeted therapy decisions.
Treatment
Osteosarcoma treatment involves multimodal therapy combining chemotherapy and surgery, typically coordinated by pediatric or orthopedic oncologists. Neoadjuvant chemotherapy is usually administered first to shrink the primary tumor and treat micrometastases, commonly including doxorubicin, cisplatin, and methotrexate with leucovorin rescue. Some protocols also incorporate ifosfamide or etoposide. Surgical options include limb-salvage procedures using endoprostheses or bone grafts when feasible, or amputation when necessary to achieve complete tumor removal. The choice between limb salvage and amputation depends on tumor location, size, response to chemotherapy, patient age, and functional considerations. Following surgery, additional chemotherapy cycles are administered, with treatment intensity often adjusted based on the degree of tumor necrosis achieved with preoperative therapy. For metastatic disease, surgical resection of pulmonary nodules may be performed alongside systemic therapy. Emerging treatments include targeted therapies such as sorafenib for refractory cases, immunotherapy agents, and novel drug combinations currently being evaluated in clinical trials.
Prognosis
Prognosis for osteosarcoma varies significantly based on disease stage at diagnosis and response to treatment. Patients with localized disease have 5-year survival rates of 60-70%, while those with metastatic disease at presentation face 20-30% survival rates. The degree of tumor necrosis following neoadjuvant chemotherapy serves as a critical prognostic factor, with greater than 90% necrosis associated with improved outcomes. Other favorable prognostic indicators include younger age, absence of metastases, complete surgical resection, normal alkaline phosphatase and LDH levels, and tumor location in extremities rather than axial skeleton. Patients who develop recurrent disease have poorer prognosis, with outcomes depending on the site and timing of recurrence. Pulmonary metastases that can be completely resected surgically offer better prospects than unresectable disease. Long-term survivors require lifelong follow-up for potential treatment-related complications, secondary cancers, and functional issues. Quality of life outcomes have improved with advances in limb-salvage techniques, rehabilitation programs, and supportive care measures.
Quality of life
Living with osteosarcoma requires significant lifestyle adjustments during and after treatment. Patients benefit from maintaining physical activity as tolerated, working with physical therapists to preserve strength and mobility throughout treatment. Nutritional support becomes crucial during chemotherapy, with focus on adequate protein intake, hydration, and managing treatment-related nausea or appetite changes. Sleep patterns may be disrupted by pain, hospital stays, or steroid medications, making sleep hygiene practices important. Mental health support through counseling, support groups, or psychiatric care helps address anxiety, depression, and adjustment challenges common in young cancer patients. Educational accommodations may be necessary during treatment, with many institutions offering hospital-based or online learning options. Social connections with peers, family, and other osteosarcoma survivors provide emotional support and practical advice. Adaptive equipment may be needed temporarily or permanently depending on surgical outcomes. Regular follow-up care includes monitoring for recurrence, managing treatment side effects, and addressing evolving physical and psychosocial needs as patients transition from active treatment to survivorship.
Pregnancy and fertility
Osteosarcoma treatment can significantly impact fertility in both males and females due to chemotherapy effects on reproductive organs. Cisplatin, doxorubicin, and ifosfamide may cause temporary or permanent infertility. Fertility preservation options should be discussed before treatment initiation, including sperm banking for males and egg or embryo cryopreservation for females. For patients who become pregnant after osteosarcoma treatment, close monitoring is essential, though most chemotherapy agents clear the system before conception becomes advisable. Pregnancy during active treatment is generally not recommended due to teratogenic effects of chemotherapy agents. Genetic counseling is important for patients with hereditary cancer syndromes, as some genetic mutations associated with osteosarcoma can be inherited. Women who have received chest radiation require cardiac evaluation before pregnancy due to potential heart complications. Breastfeeding is typically safe after completion of chemotherapy, though timing recommendations vary based on specific treatments received.
Children
Since osteosarcoma predominantly affects children and adolescents, pediatric considerations are central to care. Treatment at specialized pediatric cancer centers with multidisciplinary teams experienced in childhood bone cancers improves outcomes. Growth and development monitoring is crucial, as chemotherapy and surgery can affect bone growth, puberty, and psychosocial development. Educational support through child life specialists, school liaisons, and individualized education plans helps maintain academic progress during treatment. Family-centered care approaches recognize the impact on siblings, parents, and extended family members. Age-appropriate communication about diagnosis, treatment, and prognosis helps children understand their condition while maintaining hope and normalcy. Rehabilitation services focus on returning to age-appropriate activities, sports participation when possible, and peer interactions. Long-term survivorship care addresses potential late effects of treatment including growth abnormalities, cardiac dysfunction, hearing loss, and secondary cancers. Transition planning to adult care providers becomes important as pediatric patients mature, ensuring continuity of follow-up and understanding of ongoing health needs.
When to see a doctor
Seek immediate medical evaluation for persistent bone pain in children or adolescents that worsens over time, especially if accompanied by swelling, tenderness, or functional limitations. Red flag symptoms requiring urgent assessment include fractures from minimal trauma, rapidly growing masses near bones, severe pain that interferes with sleep or daily activities, and systemic symptoms such as unexplained weight loss or fatigue. Don’t dismiss bone pain as simple growing pains if it persists beyond 2-3 weeks, occurs primarily at night, or progressively worsens despite rest and over-the-counter pain medications. Any palpable mass or swelling around bones, particularly near the knee or shoulder, warrants prompt evaluation. For patients with cancer predisposition syndromes or previous radiation exposure, maintain heightened awareness for bone pain or changes. Following osteosarcoma treatment, contact healthcare providers immediately for new bone pain, respiratory symptoms suggesting pulmonary complications, or any concerning changes in previously treated areas.
Regional context
Limited specific data exists regarding osteosarcoma prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. However, the global incidence of approximately 3.4 cases per million annually likely applies to these regions, with potential variations based on genetic background, environmental factors, and healthcare reporting systems. Access to specialized pediatric oncology services and advanced imaging may vary across these regions, potentially affecting diagnosis timing and treatment outcomes. Regional cancer registries and healthcare institutions are encouraged to contribute epidemiological data to better understand osteosarcoma patterns in these populations. Genetic factors specific to regional populations may influence disease susceptibility or progression, warranting further research collaboration. Healthcare providers in these regions should maintain awareness of osteosarcoma symptoms and ensure appropriate referral pathways to specialized centers when local expertise is limited.
Research and clinical trials
Current osteosarcoma research focuses on improving survival rates through novel therapeutic approaches, better understanding tumor biology, and reducing treatment-related toxicity. Immunotherapy trials investigate checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines designed to enhance immune system recognition of osteosarcoma cells. Targeted therapy studies examine agents directed against specific molecular pathways active in osteosarcoma, including mTOR inhibitors, angiogenesis inhibitors, and drugs targeting DNA repair mechanisms. Combination therapy trials test novel chemotherapy regimens, radiation sensitizers, and treatment sequence optimization. Precision medicine approaches use tumor genetic profiling to match patients with targeted therapies. Clinical trials are actively recruiting patients through ClinicalTrials.gov, with studies available for newly diagnosed patients, recurrent disease, and metastatic cases. Research also emphasizes improving surgical techniques, developing better prosthetics for limb-salvage procedures, and understanding factors that predict treatment response. International collaborative groups facilitate large-scale studies necessary for this rare cancer, sharing data and resources to accelerate progress toward improved outcomes.
Frequently asked questions
Is osteosarcoma hereditary?
Most osteosarcoma cases (90-95%) occur sporadically without inherited genetic causes. However, 5-10% are associated with genetic syndromes such as Li-Fraumeni syndrome, hereditary retinoblastoma, or Rothmund-Thomson syndrome. Genetic counseling can help determine if family history suggests increased risk.
Can osteosarcoma be cured?
Yes, osteosarcoma can be cured, particularly when caught early and treated aggressively. With current multimodal therapy combining chemotherapy and surgery, 60-70% of patients with localized disease achieve long-term survival and cure. Early detection and treatment at specialized centers optimize outcomes.
Will my child need amputation?
Not necessarily. Limb-salvage surgery is now possible in 80-90% of cases involving arm or leg bones, preserving the limb while completely removing the tumor. The choice between limb salvage and amputation depends on tumor location, size, response to chemotherapy, and individual factors affecting function and safety.
How long does treatment take?
Complete osteosarcoma treatment typically requires 8-12 months, including preoperative chemotherapy (2-3 months), surgery and recovery (1-2 months), and postoperative chemotherapy (4-6 months). Treatment duration may vary based on individual response, complications, or specific protocols used.
What happens during follow-up care?
Follow-up includes regular chest imaging to monitor for lung metastases, bone scans to detect skeletal recurrence, blood tests, physical examinations, and monitoring for treatment-related side effects. Visits are frequent initially (every 3 months) and gradually decrease over time, continuing for many years to detect late recurrences or treatment complications.
Support and resources
International organizations:
- Orphanet – www.orpha.net
- National Organization for Rare Disorders (NORD) –
Cite this page
GMJ News Desk. “Osteosarcoma.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/osteosarcoma/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?
In the news